Tutorials › Biostatistics › Family-Wise Error Rate vs. False Discovery Rate

Multiple Testing & Multiplicity

Family-Wise Error Rate vs. False Discovery Rate

A practical guide to family-wise error rate (FWER) and false discovery rate (FDR), including why multiple testing creates false positives, how Bonferroni and Holm control FWER, how Benjamini–Hochberg controls FDR, and when each approach is appropriate in clinical trials and high-dimensional research.

Advanced 16 min read

What You'll Learn

  • Why testing many hypotheses creates a multiple-testing problem
  • How family-wise error rate and false discovery rate are defined
  • Why FWER control is generally more stringent than FDR control
  • How Bonferroni and Holm control FWER
  • How the Benjamini–Hochberg procedure controls FDR
  • How to choose between FWER and FDR in clinical and exploratory research

Introduction

Suppose a researcher performs one hypothesis test at the conventional significance level of 0.05. The probability of a false positive, assuming the null hypothesis is true, is at most 5%.

Now suppose the researcher performs 20 independent hypothesis tests, each at the same 0.05 significance level. The probability of obtaining at least one false positive can be substantially larger than 5%.

This is the fundamental multiple-testing problem.

Two of the most important ways to describe and control errors arising from multiple testing are the:

  • Family-wise error rate (FWER)
  • False discovery rate (FDR)

These quantities address different scientific goals. FWER asks: "What is the probability of making even one false rejection?"

FDR asks: "Among the hypotheses I reject, what proportion are expected to be false?"

Key distinction: FWER controls the probability of making at least one false discovery in the family. FDR controls the expected proportion of false discoveries among the discoveries that are made.

Why Multiple Testing Is a Problem

Consider a single null hypothesis that is tested at:

\[ \alpha=0.05 \]

If the null hypothesis is true, the probability of rejecting it incorrectly is 5%.

Now suppose there are \(m\) independent true null hypotheses, each tested at the same significance level. The probability of making no false rejection is approximately:

\[ (1-\alpha)^m \]

Therefore, the probability of making at least one false rejection is:

\[ 1-(1-\alpha)^m \]

For 20 independent tests at \(\alpha=0.05\):

\[ 1-(0.95)^{20}\approx0.6415 \]

Thus, if all 20 null hypotheses are true, there is approximately a 64.2% probability of obtaining at least one nominally significant result.

This is the multiple-testing problem: using 0.05 independently for every test does not mean the probability of at least one false positive remains 5%.

What Is a Hypothesis Family?

Both FWER and FDR require a definition of the set of hypotheses being considered. This set is commonly called the family.

For example, a clinical trial might contain:

  • One primary endpoint
  • Three key secondary endpoints
  • Several exploratory endpoints
  • Multiple treatment comparisons
  • Several dose comparisons
  • Subgroup analyses

Whether these tests belong to the same multiplicity family depends on the scientific question and the prespecified testing strategy.

Important: Multiplicity adjustment is not simply a mathematical exercise. The definition of the hypothesis family should reflect the claims the study intends to make.

Notation for Multiple Testing

Suppose there are \(m\) hypotheses:

\[ H_1,H_2,\ldots,H_m \]

After testing them, each hypothesis is either rejected or not rejected. Let:

  • \(V\) = number of rejected true null hypotheses
  • \(S\) = number of rejected false null hypotheses
  • \(R=V+S\) = total number of rejected hypotheses
  • \(m_0\) = number of true null hypotheses
  • \(m_1=m-m_0\) = number of false null hypotheses

These quantities form the foundation of FWER and FDR.

Family-Wise Error Rate

The family-wise error rate is defined as the probability of making at least one false rejection within the family.

\[ \operatorname{FWER}=P(V\ge1) \]

In words: FWER is the probability that at least one rejected hypothesis is actually a true null hypothesis.

A procedure that controls FWER at 0.05 guarantees, under the assumptions required by that procedure, that:

\[ P(V\ge1)\le0.05 \]

This is a very strong form of error control.

Why FWER Is Attractive in Confirmatory Trials

Suppose a regulatory claim is based on several hypotheses. If even one false positive could result in an unsupported efficacy claim, controlling FWER is highly relevant.

For example, a confirmatory clinical trial might have multiple primary or key secondary hypotheses whose results will support formal claims.

In this setting, the question is often: "What is the probability that I make at least one false efficacy claim?"

FWER directly addresses this question.

False Discovery Rate

The false discovery rate takes a different perspective. It is the expected proportion of false discoveries among all discoveries.

\[ \operatorname{FDR} = E\left[ \frac{V}{R} \right] \]

with the convention that:

\[ \frac{V}{R}=0 \qquad\text{when }R=0 \]

Thus FDR focuses on the quality of the collection of discoveries rather than on whether the collection contains even one false discovery.

Key difference: FWER asks whether there is any false discovery. FDR asks how large the false discovery fraction is expected to be.

A Simple Example

Suppose a study rejects 20 hypotheses. Among those 20 discoveries, suppose 2 are actually false discoveries. Then:

\[ V=2,\qquad R=20 \]

The observed false discovery proportion is:

\[ \operatorname{FDP} = \frac{V}{R} = \frac{2}{20} = 0.10 \]

or 10%.

FDR is the expectation of this quantity over repeated experiments:

\[ \operatorname{FDR}=E(\operatorname{FDP}) \]

Therefore, an FDR procedure targeting 10% attempts to ensure that the expected false discovery proportion is no greater than 10%.

FDP vs. FDR

These terms are closely related but should not be confused.

Quantity Meaning
False discoveries \(V\) Number of rejected true null hypotheses
Discoveries \(R\) Total number of rejected hypotheses
False discovery proportion \(V/R\) in one realized dataset
False discovery rate Expected value of \(V/R\) over repeated studies
FWER Probability that \(V\ge1\)

The Central Conceptual Difference

The easiest way to remember the distinction is:

Question Error Criterion
Did I make even one false discovery? FWER
What proportion of my discoveries are expected to be false? FDR

This difference explains why FDR procedures can be substantially more powerful than FWER procedures when many hypotheses are tested.

FWER Is More Stringent

Controlling FWER at 5% requires:

\[ P(V\ge1)\le0.05 \]

FDR control at 5% requires:

\[ E\left[\frac{V}{R}\right]\le0.05 \]

These are not equivalent requirements.

A procedure can permit some false discoveries while maintaining a low expected false discovery proportion.

This usually provides greater power when the goal is to identify many potential signals rather than guarantee that the entire set of discoveries contains no false positives.

Bonferroni Control of FWER

The classic Bonferroni procedure is one of the simplest methods for controlling FWER.

Suppose there are \(m\) hypotheses and the desired family-wise error rate is \(\alpha\). Instead of testing every hypothesis at \(\alpha\), test each one at:

\[ \alpha_{\text{individual}} = \frac{\alpha}{m} \]

For example, if:

\[ \alpha=0.05 \qquad\text{and}\qquad m=10 \]

then each hypothesis is tested at:

\[ \frac{0.05}{10}=0.005 \]

This guarantees FWER control by the Bonferroni inequality.

Bonferroni Using Adjusted P-Values

Instead of changing the significance threshold, one can adjust each p-value:

\[ p_i^{\text{adj}} = \min(mp_i,1) \]

A hypothesis is rejected when:

\[ p_i^{\text{adj}}\le\alpha \]

Why Bonferroni Can Be Conservative

Bonferroni treats every test as if it needs a share of the entire error budget. When there are many hypotheses, the individual threshold can become extremely small.

For example, with 100 hypotheses and a family-wise alpha of 0.05:

\[ \frac{0.05}{100}=0.0005 \]

A real signal may therefore fail to reach significance even when the effect is scientifically meaningful.

This loss of power is one reason that FDR procedures are attractive in exploratory, high-dimensional settings.

Holm's Step-Down Procedure

Holm's procedure also controls FWER but is generally less conservative than the simple Bonferroni correction.

First, sort the p-values:

\[ p_{(1)}\le p_{(2)}\le\cdots\le p_{(m)} \]

Compare the smallest p-value with:

\[ \frac{\alpha}{m} \]

The second smallest is compared with:

\[ \frac{\alpha}{m-1} \]

and so on. The \(i\)-th ordered p-value is compared with:

\[ \frac{\alpha}{m-i+1} \]

The procedure stops at the first failure.

1
Sort: Order all p-values from smallest to largest.
2
Compare: Compare \(p_{(i)}\) with \(\alpha/(m-i+1)\).
3
Continue: Continue while the ordered hypotheses pass.
4
Stop: Once a hypothesis fails, that hypothesis and all larger p-values are not rejected.

Benjamini–Hochberg Control of FDR

The most widely known FDR procedure is the Benjamini–Hochberg (BH) procedure.

Again, sort the p-values:

\[ p_{(1)}\le p_{(2)}\le\cdots\le p_{(m)} \]

For each ordered p-value, calculate the BH critical value:

\[ \frac{i}{m}q \]

where:

  • \(i\) = rank of the p-value
  • \(m\) = total number of hypotheses
  • \(q\) = desired FDR level

Find the largest \(i\) satisfying:

\[ p_{(i)} \le \frac{i}{m}q \]

Then reject all hypotheses with ranks:

\[ 1,\ldots,i \]

Worked Benjamini–Hochberg Example

Suppose ten hypotheses produce the following ordered p-values:

Rank \(i\) P-value \(i/10\times0.05\) Reject?
1 0.001 0.005 Yes
2 0.004 0.010 Yes
3 0.008 0.015 Yes
4 0.012 0.020 Yes
5 0.019 0.025 Yes
6 0.031 0.030 No
7 0.041 0.035 No
8 0.060 0.040 No
9 0.120 0.045 No
10 0.400 0.050 No

The largest rank satisfying the BH condition is:

\[ i=5 \]

Therefore, the first five hypotheses are rejected.

Bonferroni vs. Benjamini–Hochberg

Using the same ten p-values, compare Bonferroni and BH.

Bonferroni requires:

\[ p_i\le\frac{0.05}{10}=0.005 \]

Only the p-values 0.001 and 0.004 pass.

The BH procedure rejects the first five hypotheses.

Procedure Error Controlled Discoveries in Example
Bonferroni FWER 2
Holm FWER More than or equal to Bonferroni
Benjamini–Hochberg FDR 5

The BH procedure is more permissive because it controls a different and generally less stringent error criterion.

FWER vs. FDR: Side-by-Side

Feature FWER FDR
Definition \(P(V\ge1)\) \(E[V/R]\)
Primary concern Any false discovery Proportion of false discoveries
Stringency Generally more stringent Generally less stringent
Power Usually lower Usually higher
Typical use Confirmatory inference Exploratory/high-dimensional discovery
Classic procedure Bonferroni / Holm Benjamini–Hochberg

A Clinical Trial Example

Suppose a randomized clinical trial evaluates a new treatment on five secondary endpoints. The p-values are:

\[ 0.004,\quad0.012,\quad0.021,\quad0.038,\quad0.120 \]

Suppose the family-wise error rate must be controlled at 5%. Using Bonferroni:

\[ \alpha_{\text{individual}} = \frac{0.05}{5} = 0.01 \]

Only the p-value 0.004 is significant.

This may be appropriate if the study intends to make formal confirmatory claims about these endpoints.

What Happens Under FDR Control?

Suppose instead that the five endpoints are exploratory and the investigator wants to identify promising signals for future research. Using BH at:

\[ q=0.05 \]

the ordered critical values are:

\[ 0.01,\quad0.02,\quad0.03,\quad0.04,\quad0.05 \]

The first four p-values satisfy their corresponding thresholds:

  • 0.004 ≤ 0.01
  • 0.012 ≤ 0.02
  • 0.021 ≤ 0.03
  • 0.038 ≤ 0.04

Thus, BH would identify the first four as discoveries.

Interpretation: The difference is not that one procedure is "correct" and the other is "incorrect." They answer different questions. FWER is appropriate when even one false claim is problematic; FDR is attractive when the objective is to identify a collection of potentially meaningful signals while accepting a controlled proportion of false discoveries.

Why FDR Can Have Much Greater Power

Suppose a study tests 10,000 biomarkers. If Bonferroni FWER control is used at 5%, the individual threshold is:

\[ \frac{0.05}{10000}=0.000005 \]

That is an extremely stringent threshold.

Many genuine but moderate signals may not pass it.

FDR control instead allows the threshold to increase with the rank of the p-value. This can produce substantially more discoveries while maintaining control over the expected false discovery proportion.

FWER in Confirmatory Clinical Research

FWER control is particularly important when the hypotheses correspond to formal claims. Examples include:

  • Multiple primary endpoints
  • Key secondary endpoints
  • Multiple dose comparisons
  • Multiple treatment comparisons
  • Multiplicity arising from interim testing strategies
  • Confirmatory subgroup claims

The reason is straightforward: a single false positive can lead to an unsupported conclusion.

FDR in Exploratory Research

FDR is often attractive when researchers are screening large numbers of hypotheses. Examples include:

  • Genomic studies
  • Transcriptomic studies
  • Proteomic studies
  • High-throughput screening
  • Biomarker discovery
  • Large-scale imaging analyses
  • Exploratory subgroup or feature screening

In these settings, rejecting no hypotheses may be less useful than identifying a reasonably reliable collection of candidates for further investigation.

FDR Does Not Mean "5% Chance of a False Positive"

A common misunderstanding is: "FDR = 5% means each significant result has a 5% probability of being false."

That is not generally what FDR means.

FDR controls:

\[ E\left[\frac{V}{R}\right] \]

across repeated experiments under the assumptions of the procedure.

It does not automatically mean:

\[ P(H_i\text{ is true}\mid H_i\text{ was rejected})=0.05 \]

for every individual hypothesis.

Important: FDR is a property of the collection of discoveries, not a guarantee that every individual significant result has a 5% probability of being false.

FWER Does Not Mean Every P-Value Has Error Rate 5%

Likewise, FWER is a family-level criterion. A procedure controlling FWER at 5% guarantees:

\[ P(V\ge1)\le0.05 \]

It does not mean that every individual hypothesis has exactly a 5% probability of being falsely rejected.

The Role of Dependence

Hypothesis tests are often correlated. For example, clinical endpoints may be correlated, and biomarkers measured on the same patients are rarely independent.

Dependence matters because the probability of observing multiple small p-values changes with the correlation structure.

Some procedures are valid under broad dependence structures, while others require independence or specific forms of positive dependence.

Practical point: Do not assume that all multiple-testing procedures have identical theoretical properties under every dependence structure. The assumptions behind the selected procedure should be appropriate for the analysis.

Bonferroni Under Dependence

One reason Bonferroni remains popular is its simplicity and broad validity. Using the union bound:

\[ P\left(\bigcup_{i=1}^{m}\{\text{false rejection of }H_i\}\right) \le \sum_{i=1}^{m}\alpha_i \]

If the individual error allocations satisfy:

\[ \sum_{i=1}^{m}\alpha_i\le\alpha \]

then FWER is controlled at level \(\alpha\).

No independence assumption is required for this basic Bonferroni argument.

Weighted Bonferroni

Not all hypotheses necessarily have equal importance. A weighted Bonferroni strategy can allocate different portions of the error budget to different hypotheses. Let weights \(w_i\) satisfy:

\[ w_i\ge0 \]
and:

\[ \sum_{i=1}^{m}w_i=1 \]

Then hypothesis \(i\) can be tested at:

\[ \alpha_i=w_i\alpha \]

This can be useful when some hypotheses are more important than others.

FDR Is Not Always the Right Choice

The higher power of FDR procedures does not automatically make them preferable.

FDR may be inappropriate when:

  • A single false claim would be unacceptable.
  • The hypotheses support regulatory claims.
  • The analysis is confirmatory rather than exploratory.
  • There is a strong need to protect the family from any false rejection.
  • The estimand and multiplicity strategy require stronger error control.

FWER Is Not Always the Right Choice

Conversely, FWER can be unnecessarily restrictive when the scientific goal is large-scale discovery.

For example, screening 20,000 biomarkers with Bonferroni correction may result in very few discoveries, even when many genuine signals exist.

In such settings, FDR control may provide a better balance between false discoveries and discovery power.

Relationship Between FWER and FDR

There is an important mathematical relationship between the two criteria. Because:

\[ \frac{V}{R}\le I(V\ge1) \]

where \(I(\cdot)\) is an indicator function, it follows that:

\[ \operatorname{FDR} \le \operatorname{FWER} \]

under the standard convention that \(V/R=0\) when \(R=0\).

Therefore, controlling FWER at level \(\alpha\) also controls FDR at level \(\alpha\).

Important: The converse is not generally true. Controlling FDR at 5% does not generally guarantee FWER control at 5%.

A Useful Extreme Example

Suppose a procedure always produces exactly 100 discoveries and, on average, 5 are false. Then:

\[ \operatorname{FDR} = \frac{5}{100} = 0.05 \]

An FDR of 5% may therefore be acceptable. But if every one of those experiments contains at least one false discovery, then:

\[ \operatorname{FWER}\approx1 \]

Thus, an FDR procedure can have excellent FDR control while offering little FWER protection.

Why the Distinction Matters for Clinical Trials

Consider a trial with ten exploratory biomarkers. If the goal is to identify candidate biomarkers for future validation, allowing a small proportion of false discoveries may be reasonable.

If the goal is instead to make a definitive regulatory claim that a biomarker predicts treatment benefit, stronger multiplicity control may be required.

The statistical procedure should therefore follow the purpose of the inference.

R Example: Bonferroni

R makes Bonferroni adjustment straightforward.

p <- c(
  0.004, 0.012, 0.021,
  0.038, 0.120
)

p.adjust(p, method = "bonferroni")

The adjusted p-values are obtained by multiplying each p-value by the number of tests, with values capped at 1.

R Example: Holm

p.adjust(
  p,
  method = "holm"
)

Holm generally provides greater power than simple Bonferroni while maintaining FWER control.

R Example: Benjamini–Hochberg

p.adjust(
  p,
  method = "BH"
)

The resulting adjusted p-values can be compared with the desired FDR level. For example:

p_adj <- p.adjust(
  p,
  method = "BH"
)

p_adj <= 0.05

Manual Benjamini–Hochberg Calculation in R

The BH procedure can also be implemented explicitly to understand the algorithm.

p <- c(
  0.004, 0.012, 0.021,
  0.038, 0.120
)

q <- 0.05

m <- length(p)

ord <- order(p)

p_sorted <- p[ord]

critical <- (1:m) / m * q

comparison <- p_sorted <= critical

data.frame(
  rank = 1:m,
  p_value = p_sorted,
  critical_value = critical,
  reject_condition = comparison
)

Adjusted P-Values Under BH

For a sorted collection of p-values, BH-adjusted p-values are obtained by working backward through the ordered values. Conceptually:

\[ p_{(i)}^{\text{BH}} = \min_{j\ge i} \left( \frac{m}{j}p_{(j)} \right) \]

The resulting values are then mapped back to the original hypothesis order.

FWER vs. FDR in a Decision Framework

1
Are the analyses confirmatory? If yes, begin by considering FWER control.
2
Would one false claim be unacceptable? If yes, FWER is generally the relevant criterion.
3
Are hundreds or thousands of hypotheses being screened? If yes, FDR may be more appropriate.
4
Is the goal discovery rather than definitive confirmation? If yes, consider FDR control.
5
Does the protocol or statistical analysis plan prespecify a multiplicity strategy? Follow the prespecified strategy rather than choosing an adjustment after seeing the results.

Common Multiple-Testing Mistakes

  1. Running many tests at 0.05 without adjustment. The family-level false-positive probability can become much larger than 5%.
  2. Calling Bonferroni "the" multiple-testing correction. Bonferroni is one FWER procedure among many.
  3. Assuming FDR and FWER are interchangeable. They control different quantities.
  4. Interpreting FDR as the probability an individual result is false. FDR is a family-level expected proportion.
  5. Using FDR automatically because it has greater power. Higher power is not the relevant criterion if the scientific claim requires strong FWER control.
  6. Defining the testing family after looking at the results. The family and multiplicity strategy should generally be prespecified for confirmatory inference.
  7. Ignoring dependence assumptions. Different procedures have different theoretical requirements.
  8. Adjusting only the p-values that "look related." The multiplicity strategy should correspond to the complete inferential family, not simply the tests that happened to produce interesting results.
  9. Reporting unadjusted p-values as confirmatory evidence. If multiplicity adjustment is required, the adjusted inference should be reported clearly.

FWER Procedures Commonly Used in Practice

Procedure Primary Error Criterion General Characteristic
Bonferroni FWER Simple and broadly applicable
Holm FWER Step-down; usually more powerful than Bonferroni
Hochberg FWER Step-up; stronger assumptions than Holm
Hommel FWER Closed-testing-based improvement in power
Gatekeeping FWER Useful for hierarchical endpoint families
Closed testing FWER General framework for strong FWER control

FDR Procedures Commonly Used in Practice

Procedure Primary Error Criterion Typical Use
Benjamini–Hochberg FDR General multiple-discovery problems
Benjamini–Yekutieli FDR More general dependence settings
Adaptive FDR methods FDR Potentially improved power using information about true nulls

Strong vs. Weak FWER Control

Another important concept is the distinction between weak and strong control of FWER.

Weak control concerns the complete null configuration, where all hypotheses are true. Strong control requires control of FWER under every possible configuration of true and false null hypotheses.

In confirmatory clinical research, strong control is generally the relevant standard.

\[ P(V\ge1)\le\alpha \]

must hold regardless of which hypotheses are actually true.

Why Strong Control Matters

Suppose five hypotheses are tested but only two are actually true. A procedure with weak FWER control under the complete null does not necessarily guarantee adequate error control in this mixed configuration.

A strong FWER procedure is designed to protect against all such configurations.

FWER and Multiplicity in Clinical Development

Multiplicity can arise from many sources in clinical development:

  • Multiple treatment arms
  • Multiple doses
  • Multiple endpoints
  • Multiple time points
  • Multiple populations
  • Multiple estimands
  • Interim analyses
  • Subgroup analyses
  • Multiple testing strategies

These sources should not necessarily all be placed into one giant multiplicity family. The appropriate structure depends on the scientific claims and the prespecified testing strategy.

Multiplicity Is More Than P-Value Adjustment

A sophisticated multiplicity strategy may involve:

  • Hierarchical testing
  • Gatekeeping
  • Alpha allocation
  • Graphical approaches
  • Closed testing
  • Fallback procedures
  • Sequential testing
  • Combination tests

The objective is not simply to make p-values larger. The objective is to construct a valid inferential system for the complete family of claims.

Family-Wise Error Rate and Alpha Spending

Interim analyses create another form of multiplicity. If a hypothesis is tested repeatedly during a clinical trial, repeatedly using the same nominal significance threshold can inflate the overall type I error.

Sequential methods therefore allocate the total type I error across analyses.

Conceptually:

\[ \alpha_1+\alpha_2+\cdots+\alpha_K \le \alpha \]

This is related to the broader principle of controlling error across a family of statistical opportunities.

FWER vs. FDR Is a Scientific Decision

The choice should not be made solely because one procedure produces more significant results.

Ask what happens after the statistical analysis.

If a significant result will support a definitive claim, stronger error control may be appropriate.

If a significant result will instead identify a candidate for further study, FDR may provide a more useful balance between discovery and false positives.

Best practice: Choose the error criterion based on the intended scientific interpretation of the discoveries, then select an appropriate multiplicity procedure.

A Compact Numerical Comparison

Suppose 100 hypotheses are tested at an overall target of 5%.

Method Threshold / Criterion Primary Protection
Unadjusted 0.05 for every test No family-level control
Bonferroni 0.0005 per test FWER
Holm Step-down thresholds FWER
BH \(i(0.05)/100\) FDR

The unadjusted approach has the greatest nominal power but can have severe false-positive inflation. Bonferroni has strong FWER control but may be conservative. Holm retains FWER control while generally improving power. BH controls FDR and can identify substantially more discoveries in large families.

What Should Be Reported?

A multiple-testing analysis should clearly report:

  • The hypotheses included in the testing family
  • The primary error criterion
  • The nominal target level
  • The adjustment procedure
  • Whether the procedure was prespecified
  • The adjusted p-values or adjusted decision thresholds
  • The assumptions relevant to the procedure
  • How multiplicity interacts with the interpretation of the results

Example Statistical Analysis Plan Language

For a confirmatory family, the analysis plan might specify that the family-wise type I error rate will be controlled at the 5% level using a prespecified step-down procedure.

For an exploratory biomarker analysis, the plan might instead specify that false discovery rate will be controlled at 5% using the Benjamini–Hochberg procedure.

The critical point is that the chosen framework should be documented before interpreting the results.

A Practical Decision Table

Research Situation Preferred Error Concept Potential Procedure
One primary confirmatory claim FWER No multiplicity adjustment if genuinely only one hypothesis
Multiple confirmatory endpoints FWER Holm, gatekeeping, closed testing, graphical methods
Multiple dose comparisons FWER Bonferroni, Holm, specialized dose procedures
Hundreds of exploratory biomarkers FDR Benjamini–Hochberg
Thousands of genomic hypotheses FDR Benjamini–Hochberg or related FDR procedures
Regulatory efficacy claims Usually FWER Prespecified confirmatory multiplicity strategy
Exploratory signal detection Often FDR BH or related FDR procedure

The Most Important Mathematical Difference

The two criteria can be remembered through two equations. FWER:

\[ \boxed{\operatorname{FWER}=P(V\ge1)} \]

FDR:

\[ \boxed{ \operatorname{FDR} = E\left[\frac{V}{R}\right] } \]

FWER cares about whether the number of false discoveries is zero or greater than zero. FDR cares about the fraction of discoveries that are false.

A Useful Mental Model

F
FWER: "I cannot afford even one false discovery."
D
FDR: "I am willing to accept some false discoveries as long as their expected proportion among discoveries is controlled."

Common Interview Question

A common biostatistics interview question is: "What is the difference between FWER and FDR?"

A strong answer is:

FWER is the probability of making at least one false rejection among a family of hypotheses, whereas FDR is the expected proportion of false rejections among all rejected hypotheses. FWER is generally more stringent and is commonly used for confirmatory inference, while FDR is often used for exploratory, high-dimensional discovery problems where greater power is important.

Another Common Interview Question

"Does controlling FWER at 5% also control FDR at 5%?"

Yes. Since:

\[ \frac{V}{R}\le I(V\ge1) \]

taking expectations gives:

\[ \operatorname{FDR} \le \operatorname{FWER} \]

Therefore, a procedure that strongly controls FWER at 5% also controls FDR at 5%. The reverse implication does not generally hold.

Another Common Interview Question

"Why is Benjamini–Hochberg more powerful than Bonferroni?"

The key is that they control different quantities. Bonferroni protects against the probability of any false rejection. BH controls the expected proportion of false discoveries. The latter permits some false discoveries and therefore generally allows a larger rejection set.

Summary of the Major Procedures

Procedure Controls Relative Stringency Typical Setting
Bonferroni FWER High Simple confirmatory multiplicity
Holm FWER High but less conservative than Bonferroni General confirmatory testing
Hochberg FWER Less conservative than Holm in suitable settings Confirmatory testing under relevant assumptions
Hommel FWER Powerful FWER procedure Multiple confirmatory hypotheses
Benjamini–Hochberg FDR Less stringent Exploratory/high-dimensional discovery
Benjamini–Yekutieli FDR More conservative than BH Broader dependence settings

Practical Workflow

1
Define the scientific claims being tested.
2
Define the hypothesis family.
3
Determine whether the analysis is confirmatory or exploratory.
4
Decide whether protection against any false discovery is required.
5
Choose FWER or FDR as the primary error criterion.
6
Select an appropriate multiple-testing procedure.
7
Prespecify the procedure and error level.
8
Perform the analyses and calculate adjusted p-values or rejection thresholds.
9
Report the error criterion and adjustment method clearly.
10
Interpret the discoveries according to the selected error-control framework.

Final Takeaways

The distinction between FWER and FDR is fundamental to modern statistical inference.

FWER controls the probability of making at least one false discovery:

\[ \boxed{\operatorname{FWER}=P(V\ge1)} \]

FDR controls the expected proportion of false discoveries among the discoveries:

\[ \boxed{ \operatorname{FDR} = E\left[\frac{V}{R}\right] } \]

FWER is generally more conservative and is particularly important for confirmatory claims where a single false positive can be consequential.

FDR is generally more powerful and is particularly useful when the objective is to discover a collection of promising signals among a very large number of hypotheses.

Bottom line: Use FWER when the central concern is controlling the chance of even one false claim. Use FDR when the scientific objective is large-scale discovery and a controlled proportion of false discoveries is acceptable. Bonferroni and Holm are classic FWER procedures; Benjamini–Hochberg is the classic FDR procedure. The correct choice depends on the scientific purpose of the analysis, the importance of individual claims, the number of hypotheses, and the prespecified inferential strategy.

References

Bonferroni, C.E. (1936). Teoria statistica delle classi e calcolo delle probabilità. Pubblicazioni del R. Istituto Superiore di Scienze Economiche e Commerciali di Firenze.
Holm, S. (1979). A simple sequentially rejective multiple test procedure. Scandinavian Journal of Statistics, 6(2), 65–70.
Benjamini, Y. & Hochberg, Y. (1995). Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society: Series B, 57(1), 289–300.
Benjamini, Y. & Yekutieli, D. (2001). The control of the false discovery rate under dependency. Annals of Statistics, 29(4), 1165–1188.
Hochberg, Y. (1988). A sharper Bonferroni procedure for multiple tests of significance. Biometrika, 75(4), 800–802.
Hommel, G. (1988). A stagewise rejective multiple test procedure based on a modified Bonferroni test. Biometrika, 75(2), 383–386.
Westfall, P.H. & Young, S.S. (1993). Resampling-Based Multiple Testing: Examples and Methods for P-Value Adjustment. Wiley.

Clinical Trials

See multiplicity adjustment in real clinical trials

See the method applied to published trial results, with the estimates, confidence intervals and interpretation explained.

FOURIER
Independent statistical analysis of the FOURIER phase 3 trial of evolocumab versus placebo in subjects with elevated cardiovascular risk and dyslipidemia, including…
Phase 3 · n = 27,564
ODYSSEY OUTCOMES
Complete statistical analysis of ODYSSEY OUTCOMES, the randomized phase 3 trial of alirocumab versus placebo after acute coronary syndrome, including time-to-event endpoints,…
Phase 3 · n = 18,924
E5103
Independent statistical analysis of E5103 (NCT00433511), a randomized phase 3 trial evaluating doxorubicin, cyclophosphamide, and paclitaxel with or without bevacizumab in breast…
Phase 3 · n = 4,994
LUME-Lung 1
Complete statistical analysis of LUME-Lung 1, the phase 3 randomized trial of BIBF 1120 plus docetaxel versus placebo plus docetaxel in second-line…
Phase 3 · n = 1,314
SWITCH 2
Independent statistical analysis of SWITCH 2, a randomized double-blind crossover phase 3 trial comparing insulin degludec with insulin glargine in subjects with…
Phase 3 · n = 721
GOLDEN-3
Independent statistical analysis of GOLDEN-3 (NCT02347761), a randomized phase 3 trial of nebulized SUN-101 in patients with COPD, including its FEV1 endpoint,…
Phase 3 · n = 653
See all 16 trials using multiplicity adjustment →